FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BIENAIME JEAN JACQUES
2. Issuer Name and Ticker or Trading Symbol

BIOMARIN PHARMACEUTICAL INC [ BMRN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.
3. Date of Earliest Transaction (MM/DD/YYYY)

5/8/2020
(Street)

SAN RAFAEL, CA 94901
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 5/8/2020 (1) M  20000 A$21.51 318552 D  
Common Stock 5/8/2020 (1) S  20000 D$91.72 298552 D  
Common Stock         247958 I Shares held by Jean-Jacques Bienaime Family Trust 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy Common Stock) $21.51 5/8/2020 (1) M     20000  11/12/2010 5/11/2020 Common Stock 20000 $0 0 (2)D  

Explanation of Responses:
(1) Trade made pursuant to a 10b5-1 plan executed on November 13, 2019.
(2) Reflects the number of options outstanding after the transactions from this specific stock option grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
BIENAIME JEAN JACQUES
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO ST.
SAN RAFAEL, CA 94901
X
Chief Executive Officer

Signatures
/s/ Eric Fleekop, Attorney-in-Fact5/12/2020
**Signature of Reporting PersonDate

BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more BioMarin Pharmaceutical Charts.
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more BioMarin Pharmaceutical Charts.